Chemotherapy does not improve long-term outcomes in patients with early-stage invasive lobular carcinoma, according to a meta-analysis.
Long-acting G-CSF can reduce the risk of hospitalization related to febrile neutropenia in patients with DLBCL treated with R-CHOP.
Researchers report on the safety data from the phase 3 ASCENT trial of sacituzumab govitecan in the treatment of metastatic triple-negative breast cancer.
Patients with advanced urothelial carcinoma treated with first-line enfortumab vedotin plus pembrolizumab had a 93.3% disease control rate.
Combination treatment with the GX-188E vaccine and pembrolizumab can elicit responses in patients with HPV 16-/18-positive advanced cervical cancer.
The aim of this trial was to evaluate the efficacy and safety of orelabrutinib with RCHOP in patients with extranodal non-GCB DLBCL.
Researchers sought to measure outcomes for cancer-related fatigue in patients with advanced cancer treated with open-label placebo, compared with a waitlist control group.
Researchers sought to determine whether PLM60 with pegaspargase would have efficacy in patients with extranodal natural killer/T-cell lymphoma.
A report suggests the timing of range-of-motion exercises after breast cancer surgery may affect flexion range of motion without affecting wound outcomes.
Adding liposomal irinotecan to 5-fluorouracil and leucovorin can improve outcomes in gemcitabine-refractory, advanced pancreatic cancer, a phase 3 study suggests.
Researchers sought to determine the long-term efficacy of cladribine in patients with hairy cell leukemia.
Researchers sought to measure real-world adherence to patient-reported outcomes monitoring as a cancer care metric.
Researchers sought to identify genomic features in patients with large B-cell lymphoma that are linked with anti-CD19 CAR-T therapy.
The incidence of cutaneous T-cell lymphoma in the United States increased from 2000 to 2018, with an annual percent change of 0.61%.
Researchers at Brigham and Women’s Hospital investigated the skin cancer prevention behaviors of these rarely studied ethnic groups.
Investigators characterized practice patterns in the first-line treatment of nonmetastatic castration-resistant prostate cancer using real-world data.
Conditioning with MEL200 or BUMEL produced similar outcomes at 7 years.
Besremi is a monopegylated, long-acting interferon, which exhibits its cellular effects in the bone marrow in polycythemia vera.
Researchers sought to understand the significance of increasing detection rates of adrenal tumors due to improved imaging technologies.
Study results describe how genetic test results influence adherence to breast cancer surveillance recommendations among women with variants of uncertain significance vs those with pathogenic variants.